CBS and Dravet syndrome: The primary endpoint in clinical trials should emphasize neurocognition, a domain of profound clinical importance in DS and one where preclinical evidence with pharmacological CBS inhibition [24,27] or genetic CBS normalization [19] suggests efficacy.